{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:11:25Z","timestamp":1768345885284,"version":"3.49.0"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS083385"],"award-info":[{"award-number":["NS083385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG049479"],"award-info":[{"award-number":["AG049479"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG056363"],"award-info":[{"award-number":["AG056363"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG058015"],"award-info":[{"award-number":["AG058015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARG\u201016\u2010443584"],"award-info":[{"award-number":["AARG\u201016\u2010443584"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:label\/><jats:p>\u03b54 allele of ApoE is the strongest genetic risk factor for late onset Alzheimer's disease (AD). Supplementation of ApoE proteins or mimetics has been pursued for drug developments against AD. A high\u2010density lipoprotein (HDL) mimetic peptide 4F was shown to alleviate AD\u2010related deficits in APP transgenic mice, and this editorial highlights a study by Chernick <jats:italic>et\u00a0al.<\/jats:italic> who use both mouse and human neuroglial cells to explore the mechanism underlying beneficial effects of this peptide. The authors demonstrate that 4F peptide significantly increased the secretion and lipidation of ApoE in the absence and presence of A\u03b2 independent of <jats:italic>de novo<\/jats:italic> transcription\/translation, but requiring ABCA1 and the integrity of the secretory pathway between ER and Golgi. This study reveals a novel mechanism of HDL mimetic peptide as a functional ApoE enhancer and support further development of ApoA\u2010I 4F peptide as effective ApoE modulating agents against AD.<\/jats:p><\/jats:sec><jats:sec><jats:label\/><jats:p>\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/jnc14595-fig-0002-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text>\n<\/jats:p><\/jats:sec>","DOI":"10.1111\/jnc.14595","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T11:35:50Z","timestamp":1543232150000},"page":"580-583","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["<scp>HDL<\/scp> mimetic peptides affect apolipoprotein E metabolism: equal supplement or functional enhancer?"],"prefix":"10.1111","volume":"147","author":[{"given":"Wenzhang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology Case Western Reserve University Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-6508","authenticated-orcid":false,"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pathology Case Western Reserve University Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600214-JLR200"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8346443"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14554"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S12983"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.03.007"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-122377"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.01.045"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.06.026"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.263"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.05.040"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-8-9"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)41536-6"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000334914"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0361-4"}],"updated-by":[{"DOI":"10.1111\/jnc.14690","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000}}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.14595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jnc.14595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T14:31:22Z","timestamp":1694356282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.14595"}},"subtitle":["An Editorial for \u2018High-density lipoprotein mimetic peptide 4F mitigates amyloid-\u03b2-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia' on page 647."],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/jnc.14595"],"URL":"https:\/\/doi.org\/10.1111\/jnc.14595","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1111\/jnc.14690","asserted-by":"object"}]},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"2018-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}